You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

parimparib

Showing 1 - 1 of 1
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Parimparib
  • +2 more
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023